CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer.

IF 2.8 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

European Journal of Medical Research Pub Date : 2025-03-15 DOI:10.1186/s40001-025-02293-0

Kang He, Jingying Zheng, Tingyu Zhang, Hao Lv, Kai Wang, Zeyu Wang, Longyun Wang, Shan Wu, Lijing Zhao

{"title":"CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer.","authors":"Kang He, Jingying Zheng, Tingyu Zhang, Hao Lv, Kai Wang, Zeyu Wang, Longyun Wang, Shan Wu, Lijing Zhao","doi":"10.1186/s40001-025-02293-0","DOIUrl":null,"url":null,"abstract":"Background: The rise in endometrial cancer rates globally calls for advanced diagnostic methods and new biomarkers. CPA4, known for its role in cancer development, has not yet been studied in relation to endometrial cancer, making it a promising research avenue.Methods: We analyzed CPA4's mRNA expression using data from TCGA and GEO databases and validated these findings with 116 clinical samples through immunohistochemical analysis. The Ishikawa and Hec-1-A cell lines were used to examine CPA4's functionality. In addition, we conducted correlation analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and survival analysis to understand CPA4's role in endometrial cancer prognosis. A nomogram model was developed for clinical prognostic predictions.Results: CPA4 is significantly overexpressed in endometrial cancer, correlating with tumor progression and poor prognosis. Overexpression is linked to crucial functions, such as mitosis and cell cycle. Reducing CPA4 in cell lines inhibited tumor growth and spread. Kaplan-Meier plots and Cox regression analysis confirmed CPA4's significance in prognosis, with our predictive model showing high accuracy.Conclusions: CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, presenting a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"174"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909866/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02293-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The rise in endometrial cancer rates globally calls for advanced diagnostic methods and new biomarkers. CPA4, known for its role in cancer development, has not yet been studied in relation to endometrial cancer, making it a promising research avenue.

Methods: We analyzed CPA4's mRNA expression using data from TCGA and GEO databases and validated these findings with 116 clinical samples through immunohistochemical analysis. The Ishikawa and Hec-1-A cell lines were used to examine CPA4's functionality. In addition, we conducted correlation analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and survival analysis to understand CPA4's role in endometrial cancer prognosis. A nomogram model was developed for clinical prognostic predictions.

Results: CPA4 is significantly overexpressed in endometrial cancer, correlating with tumor progression and poor prognosis. Overexpression is linked to crucial functions, such as mitosis and cell cycle. Reducing CPA4 in cell lines inhibited tumor growth and spread. Kaplan-Meier plots and Cox regression analysis confirmed CPA4's significance in prognosis, with our predictive model showing high accuracy.

Conclusions: CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, presenting a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.

查看原文本刊更多论文

子宫内膜癌中CPA4过表达与预后不良及肿瘤进展相关。

背景：全球子宫内膜癌发病率的上升需要先进的诊断方法和新的生物标志物。CPA4因其在癌症发展中的作用而闻名，但尚未有人研究过它与子宫内膜癌的关系，因此它是一个很有前景的研究途径：我们利用 TCGA 和 GEO 数据库中的数据分析了 CPA4 的 mRNA 表达，并通过免疫组化分析对 116 份临床样本进行了验证。我们使用石川和 Hec-1-A 细胞系来检测 CPA4 的功能。此外，我们还进行了相关性分析、基因本体（GO）、京都基因和基因组百科全书（KEGG）、基因组富集分析（GSEA）和生存分析，以了解 CPA4 在子宫内膜癌预后中的作用。结果发现：CPA4在子宫内膜癌预后中显著过表达：结果：CPA4在子宫内膜癌中明显过表达，与肿瘤进展和预后不良相关。过表达与有丝分裂和细胞周期等关键功能有关。降低细胞系中的 CPA4 可抑制肿瘤生长和扩散。Kaplan-Meier图和Cox回归分析证实了CPA4在预后中的重要性，我们的预测模型显示出很高的准确性：结论：CPA4 是诊断和预后子宫内膜癌的重要生物标志物，为研究和临床应用提供了一条新途径。该研究强调了其作为临床工具的潜力，为改善子宫内膜癌患者管理和治疗策略铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medical Research 医学-医学：研究与实验

CiteScore

3.20

自引率

0.00%

发文量

247

审稿时长

>12 weeks

期刊介绍： European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.